Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (MARS-NIS)

NCT05129241 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05129241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05129241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (MARS-NIS)
Lead sponsor
Sanofi
Phase
Observational
Overall status
Completed
Start date
November 18, 2021
Completion date
February 16, 2023
Enrollment
163 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic cardiovascular disease, primary hypercholesterolaemia and mixed dyslipidaemia